F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6178-6190

  Zhang, Xinchao ^a   Kong, Ye ^a   Xu, Xia ^a   Xing, Huaixin ^b   Zhang, Yingjie ^b   Han, Fengjuan ^a   Li, Wenjuan ^a   Yang, Qing ^a   Zeng, Jiping ^a   Jia, Jihui ^a   Liu, Zhifang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

CyclinD1; FBXO31; Gastric cancer; miR 17; miR 20a

Indexed keywords

CYCLIN D1; F BOX PROTEIN; MICRORNA; MICRORNA 17; MICRORNA 20A; PROTEIN FBXO31; UNCLASSIFIED DRUG; FBXO31 PROTEIN, HUMAN; MESSENGER RNA; MIRN17 MICRORNA, HUMAN; MIRN20 MICRORNA, HUMAN; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GRADING; CANCER INFILTRATION; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; RNA EXTRACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DRUG SCREENING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; F-BOX PROTEINS; FEMALE; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906254304     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2183     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.PLoS One. 2012;7(7):e40364. doi: 10.1371/ journal.pone.0040364.
3. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666-673.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
5. Yang Q, Wang B, Gao W, Huang S, Liu Z, Li W, Jia J.SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-?B/Cyclin D1 signaling.Mol Cancer Res. 2013; 11(12):1497-1507.
6. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 1996;86:263-274.
7. Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW.F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 1997;91: 209-219.
8. Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T, Lasorella A, Iavarone A, Chang S, Hernando E, Pagano M. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature. 2008;452:365-369.
9. Seki A, Coppinger JA, Du H, Jang CY, Yates JR, Fang G. Plk1-and beta-TrCP-dependent degradation of Bora controls mitotic progression. J Cell Biol. 2008;181:65-78.
10. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004; 18: 2573-2580.
11. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a family of human F-box proteins. Curr Biol.1999;9: 1177-1179.
12. Vadhvani M, Schwedhelm-Domeyer N, Mukherjee C, Stegmüller J. The centrosomal E3 ubiquitin ligase FBXO31-SCF regulates neuronal morphogenesis and migration.PLoS One. 2013;8(2):e57530.doi: 10.1371/ journal.pone.0057530.
13. Santra MK, Wajapeyee N, Green MR.F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 2009 ;459(7247): 722-725.
14. Shiloh Y.FBXO31: a new player in the ever-expanding DNA damage response orchestra. Sci Signal. 2009 ;2(96):pe73. doi: 10.1126/scisignal.296pe73.
15. Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF.FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res. 2005 ;65(24):11304-11313.
16. Huang HL, Zheng WL, Zhao R, Zhang B, Ma WL. FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 2010;24(3):715-720.
17. Kogo R, Mimori K, Tanaka F, Komune S, Mori M. FBXO31 determines poor prognosis in esophageal squamous cell carcinoma. Int J Oncol. 2011;39(1):155-159.
18. Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies:where they stand. Cell Death Dis. 2012;3:e411.
19. Starostina NG, Kipreos ET. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol. 2012;22:33-41.
20. Liu Z, Chen L, Zhang X, Xu X, Xing H, Zhang Y, Li W, Yu H, Zeng J, Jia J. RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.J Cell Mol Med. 2014 ;18(4):610-623
21. Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, Yu H, Jia J, Chen C. Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma andnegatively regulated by hsa-miR-212.PLoS One. 2013 ;8(7): e69784. doi: 10.1371/journal.pone.0069784.
22. Chen BB, Glasser JR, Coon TA, Mallampalli RK. F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest.Oncogene. 2012;31(20):2566-2579.
23. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol.2004; 5:739-751.
24. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, Hershko A. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nat Cell Biol. 2001;3:321-324.
25. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci. 2003;100:10231-10236.
26. Tedesco D, Lukas J and Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Genes Dev 2002;16: 2946-2957.
27. Hiramatsu Y, Kitagawa K, Suzuki T, Uchida C, Hattori T, Kikuchi H, Oda T, Hatakeyama S, Nakayama KI, Yamamoto T, Konno H, Kitagawa M. Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination. Cancer Res. 2006;66: 8477-8483.
28. Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI and Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem. 2008;283: 30540-30548.
29. Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A, Kitagawa M. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 2009;28:2393-2405.
30. Mao JH, Kim IJ, Wu D, Cliiment J, Kang HC, DelRosario R, Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.Science. 2008;321: 1499-1502.
31. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A, Aifantis I. The SCF FBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.J Exp Med. 2007;204:1825-35.
32. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.J Exp Med. 2013;210(8):1545-1557.
33. Li J, Guo Y, Liang X, Sun M, Wang G, De W, Wu W. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.J Cancer Res Clin Oncol. 2012;138(5):763-774.
34. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, mohara H, Baba Y, Mimori K, Baba H. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma.Br J Cancer. 2012 ;106(1):182-188.
35. Xu Y, Sengupta T, Kukreja L, Minella AC. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.J Biol Chem. 2010; 285(45): 34439-34446.
36. Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grandér D, Sangfelt O. MiRNA-27a controls FBW7/ hCDC4-dependent cyclin E degradation and cell cycle progression.Cell Cycle. 2011;10(13):2172-2183.
37. Savita U, Karunagaran D. MicroRNA-106b-25 cluster targets ß-TRCP2, increases the expression of Snail and enhances cell migration and invasion in H1299 (non small cell lung cancer) cells.Biochem Biophys Res Commun. 2013 ;434(4):841-847.
38. Sanchez N, Gallagher M, Lao N, Gallagher C, Clarke C, Doolan P, Aherne S, Blanco A, Meleady P, Clynes M, Barron N. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3.PLoS One.2013;8(6):e65671.doi: 10.1371/journal. pone.0065671.
39. Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, Zhao C, Tao Y, Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer.Mol Med Rep. 2012;5(6):1514-1520.
40. Wang M, Gu H, Qian H, Zhu W, Zhao C, Zhang X, Tao Y, Zhang L, Xu W. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation.Eur J Cancer. 2013;49(8):2010-2021.